Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.34 |
| ▸ | CCR9 | P51686 | 6/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305602 | 0.87 | KEAP1 (0.36) | TP53SMN1; SMN2PTGER2CCR9CA12 | |
| SCHEMBL14303616 | 0.83 | CCR9 (0.30) | CCR9 | |
| SCHEMBL306561 | 0.78 | HSD17B2 (0.51) | CCR9PIK3CD | |
| SCHEMBL14310298 | 0.78 | CCR9 (0.31) | CCR9 | |
| SCHEMBL13455916 | 0.73 | TRPM8 (0.33) | TP53SMN1; SMN2PTGER2CCR9TRPM8 | |
| SCHEMBL14303218 | 0.72 | CCR9 (0.33) | CCR9PIK3CD | |
| SCHEMBL10223574 | 0.68 | HSD17B2 (0.52) | CCR9 | |
| SCHEMBL10223070 | 0.67 | CCR9 (0.47) | CCR9PIK3CD | |
| SCHEMBL308098 | 0.66 | TRPM8 (0.42) | TP53SMN1; SMN2CCR9TRPM8KEAP1 | |
| SCHEMBL1762607 | 0.66 | CCR9 (0.48) | CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | TP53 4185/4885SMN1; SMN2 1898/4885PTGER2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.